FDA Definition SHOCKER: When Does a Breakthrough Become a 'Generic' in the Eyes of the Regulators...

The precise criteria distinguishing a true New Molecular Entity (NME) from a subsequent 505(b)(2) application is surprisingly sharp. A molecule earns its NME status only if it has *never* received FDA approval, either stand-alone or in any combination product. The moment that initial hurdle is cleared—even when approved for a completely different therapeutic area or patient population—the compound immediately shifts its regulatory classification to 505(b)(2), which is often considered to follow a more generic pathway. Understanding this single point of demarcation reveals a key lever in pharmaceutical strategy.
#FDA #NME #505b2 #DrugDevelopment #Pharmaceuticals #RegulatoryAffairs #Biotech

Видео FDA Definition SHOCKER: When Does a Breakthrough Become a 'Generic' in the Eyes of the Regulators... канала Dan Sfera